高级搜索

基于肿瘤出芽与三级淋巴结构空间关系的头颈部鳞状细胞癌免疫表型分型

Immunophenotyping of head and neck squamous cell carcinoma based on spatial relationship between tumor budding and tertiary lymphoid structures

  • 摘要: 目的 构建并验证基于肿瘤出芽(TB)与三级淋巴结构(TLS)的头颈部鳞状细胞癌(HNSCC)免疫表型分型体系。 方法 纳入2016年1月至2022年12月两中心根治性切除的1405例患者作为训练队列,纳入2023年3月至2024年12月连续入组的502例患者作为前瞻性时间验证队列。采用HE染色评估TB,采用CD20/CD3、CD21及Ki-67评估TLS及其成熟度和空间位置。根据TB高低及TLS活性分为免疫活化型、免疫平衡型、免疫排斥型和免疫枯竭型。采用Kaplan-Meier法、Cox回归、交互作用分析及时间依赖ROC评价其预后价值,并在训练队列的100例mIHC子集中进行探索性空间免疫分析。 结果 训练队列四型5年总生存率分别为84.6%、67.8%、55.1%和29.7%(P<0.001);与免疫活化型相比,免疫平衡型、免疫排斥型和免疫枯竭型校正死亡风险逐渐升高,HR分别为1.82、2.46和4.28。验证队列四型2年总生存率分别为94.0%、84.9%、76.2%和57.8%(P<0.001),免疫枯竭型校正HR为3.91。加入TB-TLS分型后,训练队列C-index由0.724升至0.769,验证队列由0.711升至0.751。mIHC分析显示,四型间效应细胞密度、效应-耗竭比值及TB周围免疫细胞分布存在梯度差异。 结论 TB与TLS联合分型可能在传统临床病理因素基础上提供附加预后分层信息,但其临床应用价值和治疗预测意义仍需多中心独立队列进一步验证。

     

    Abstract: Objective: To develop and validate an immunophenotyping system based on tumor budding (TB) and tertiary lymphoid structures (TLS) for head and neck squamous cell carcinoma (HNSCC). Methods: A total of 1405 patients undergoing radical resection from January 2016 to December 2022 were enrolled as the training cohort, and 502 consecutive patients enrolled from March 2023 to December 2024 were enrolled as the prospective time validation cohort. HE staining was used to evaluate TB, and CD20/CD3, CD21 and Ki-67 were used to evaluate TLS and its maturity and spatial location. According to the level of TB and TLS activity, the patients were divided into immune activation type, immune balance type, immune rejection type and immune depletion type. Kaplan-Meier method, Cox regression, interaction analysis, and time-dependent ROC curve were used to evaluate the prognostic value. Exploratory spatial immunoassay was performed in a subset of 100 mIHC patients in the training cohort. Results: In the training cohort, the 5-year overall survival rates were 84.6%, 67.8%, 55.1% and 29.7%, respectively (P<0.001). Compared with the immune activation type, the immune balance type, immune rejection type, and immune depletion type gradually increased the adjusted risk of death, with HR of 1.82, 2.46, and 4.28, respectively. In the validation cohort, the 2-year OS rates of the four types were 94.0%, 84.9%, 76.2% and 57.8%, respectively (P<0.001), and the adjusted HR was 3.91 for the immunodepleted type. After adding TB-TLS, the C-index increased from 0.724 to 0.769 in the training cohort and from 0.711 to 0.751 in the validation cohort. mIHC analysis showed that there were gradient differences in the density of effector cells, the effector-depletion ratio and the distribution of immune cells around TB among the four types. Conclusions: The combined classification of TB and TLS may provide additional prognostic stratification information on the basis of traditional clinicopathological factors. However, its clinical application and treatment prediction value still need to be further verified by multi-center independent cohorts.

     

/

返回文章
返回